Breast Cancer

Updates of Key Studies Differ on Relative Benefit of Nab-Paclitaxel in Breast Cancer

Two important studies, both updates of earlier findings and presented at the 2017 San Antonio Breast Cancer Symposium, provided different findings as to...

Bladder Cancer

Avelumab in Advanced Urothelial Carcinoma: Further Study Needed to Clarify its Role

As reviewed in this issue of The ASCO Post, Patel and colleagues have presented data from the phase I JAVELIN study evaluating avelumab in platinum-refractory...

Breast Cancer

ASCO/CCO Focused Guideline Update on Role of Bone-Modifying Agents in Metastatic Breast Cancer

As reported by Catherine Van Poznak, MD, FASCO, of the University of Michigan, Ann Arbor, and colleagues in the Journal of Clinical Oncology, ASCO and Cancer Care Ontario...


Advertisement

More Top Stories

Solid Tumors

Jeffrey M. Holzbeierlein, MD, on Penile, Urethral, and Testicular Cancers: Abstract Roundup

Hematologic Malignancies

Novel Agent Appears Active in Advanced or Aggressive Systemic Mastocytosis

THE INVESTIGATIONAL agent BLU-285 (avapritinib) has shown significant activity in patients with advanced or aggressive forms of systemic mastocytosis, a rare blood disorder that originates in mast cells, according to the findings of a phase I trial reported at the 2017 American Society of...

Advertisement

Family History Increases Breast Cancer Risk, Even in Women Aged 65 and Older

Family history of breast cancer continues to significantly increase chances of developing invasive breast tumors in women aged 65 years and older, according to research published by Braithwaite et al in JAMA Internal Medicine. The findings could impact mammography screening decisions later in life. ...

Pancreatic Cancer

Ramesh K. Ramanathan, MD, on Metastatic Pancreatic Cancer: Results From a SWOG Study

Alexis A. Thompson, MD, MPH, Appointed 2018 ASH President

Alexis A. Thompson, MD, MPH, an expert in sickle cell disease and thalassemia, will serve as President of the American Society of Hematology (ASH) for a 1-year term through December 2018. Dr. Thompson is Head of the Hematology Section of the Division of Hematology Oncology Transplantation and...

Solid Tumors

Pathology Laboratory: Bordeaux, France 1889

  The text and photograph on this page are excerpted from a four-volume series of books titled Oncology Tumors & Treatment: A Photographic History, by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photo below is from the volume titled “The Antiseptic Era: 1876–1900.” The photograph...

Association of MHC Class II and PD-L1 Expression With Outcome in Classical Hodgkin Lymphoma

As reported in the Journal of Clinical Oncology, Roemer et al found that programmed death cell ligand 1 (PD-L1) expression and major histocompatibility complex (MHC) class II positivity on Hodgkin Reed-Sternberg (HRS) cells may predict favorable outcome with programmed cell death protein 1 (PD-1)...

Gastroesophageal Cancer

Pieter van der Sluis, MD, PhD, on Esophageal Cancer: Results From a Surgical Treatment Trial

Breast Cancer

Bone-Modifying Agents in Metastatic Breast Cancer: Time to De-escalate Dosing Intervals

AS REVIEWED in this issue of The ASCO Post, ASCO and Cancer Care Ontario (CCO) have issued an updated guideline on the role of bone-modifying agents in metastatic breast cancer.1 The updated guideline supports a change in clinical practice for our patients with breast cancer and bone metastasis....

Advertisement

FDA’s Oncologic Drugs Advisory Committee to Review Potential New Use of Blinatumomab

On February 14, Amgen announced that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data supporting the supplemental biologics license application (sBLA) for blinatumomab (Blincyto) for the treatment of patients with minimal residual disease...